Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

38.25 +1.31 (+3.55%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Market Whales and Their Recent Bets on MRNA Options
Via Benzinga
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. 
Via MarketBeat
Exposures COVID-19
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
What the Options Market Tells Us About Moderna
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $6,300 Today
Via Benzinga
Moderna's Ongoing Decline
Another wipeout: this one, the lovely pharma opportunists at Moderna (MRNA), which has already lost 80% of its value. Just 20% to go! 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Expanding the Cloud for AI
Amazon, Alphabet, Microsoft, and Meta are all spending a ton of money to build out cloud capabilities to fuel the next phase of AI growth. But the market isn't sold on that spend yet. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Undervalued Stocks With Room to Rally Even Higher
The latest market sell-off could be a great time to give the slate of undervalued stocks another look before tech reverses course. 
Via InvestorPlace
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
Moderna sustained a rare downgrade on Monday following its guidance cut for the year. 
Via Investor's Business Daily
Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates
Via ACCESSWIRE
Home Depot To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID-19 vaccines shifted. R&D expenses rose due to late-stage oncology... 
Via Benzinga
Exposures COVID-19
MicroStrategy, Intel And Moderna Are Among Top 12 Large Cap Losers Last Week (July 28-August 3): Are The Others In Your Portfolio?
12 worst-performing large-cap stocks in the last week. Symbotic, Intel, Snap, Moderna, Mobileye, Pinterest, Arm, Entegris, Atlassian, MicroStrategy, New Oriental, and Western Digital. 
Via Benzinga
Cathie Wood Bought This Stock After Its 27% Drop. Should You?
This biotech company's promising pipeline could result in multibillion-dollar revenue. 
Via The Motley Fool
Where Will Novavax Be in 5 Years?
Its been a good year so far for the biotech, but how long can it keep the momentum going? 
Via The Motley Fool
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down from $4B. Analysts adjust price targets, citing competitive pressures from... 
Via Benzinga
Exposures COVID-19
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
Apple and Meta had strong results, while AI spending remains robust. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood's Ark Adds Over $19M Worth Of Moderna Shares After Thursday's 21% Plunge On Guidance Cut
Moderna's vaccine magic is slowly losing its charm, as evidenced by the warning the company issued on Thursday but Ark reposed its faith in the company. 
Via Benzinga
3 AI-Powered Healthcare Stocks Transforming Medicine
Invest in AI healthcare stocks to benefit significantly from tech that could propel the healthcare market to $148.4 billion by 2029. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
US Stocks Close Lower As Apple, Amazon Report Earnings: Greed Index Moves To 'Fear' Zone
The CNN Fear and Greed index fell to 39.6, signaling Fear in the market. Dow Jones dropped 495 points, Nasdaq down 2.3%, S&P 500 down 1.37%. 
Via Benzinga
Topics Stocks
Exposures US Equities
MRNA Investors Have Opportunity to Join Moderna, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Crude Oil Moves Lower; Moderna Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Stock Of The Day: Moderna Stock Plunges, Breaking Key Support Levels Following Earnings Report
Shares of Moderna (MRNA) have broken an important support level. This means a new downtrend may be forming. 
Via Benzinga
Moderna (MRNA) Q2 2024 Earnings Call Transcript
MRNA earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks To Watch Today: MRNA, META, And AMAT
Meta Platforms surged on strong earnings and AI progress, while Moderna plummeted after slashing its sales outlook and Applied Materials saw its stock drop after being denied funding under the CHIPS... 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Moderna CEO Stephane Bancel On Q2 Results, Slashing Its Full-Year Sales Guidance
Moderna reported its latest quarterly earnings. 
Via Talk Markets
Moderna Stock Sinks On Lowered 2024 Outlook, Cites Low European Sales, Competitive RSV Vaccine Market
Moderna's stock drops after cutting 2024 sales forecast due to reduced COVID-19 vaccine demand. The company now expects net sales of $3-$3.5 billion. Q2 revenue hits $241 million, beating expectations,... 
Via Benzinga
Exposures COVID-19
Moderna Slashes Its Outlook On 'Very Low' European Sales Despite Quarterly Beat
Moderna delivered nearly double the sales analysts expected in the second quarter. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.